期刊文献+

c-Jun蛋白在肝细胞癌中的表达及其意义 被引量:7

Expression of c-Jun in hepatocellular carcinoma and its significance
原文传递
导出
摘要 目的探讨c-Jun蛋白在肝细胞癌(肝癌)中的表达及其与预后的关系。方法回顾性分析2010年1月至2013年12月在中山大学附属第三医院行肝切除术的137例肝癌患者临床资料。其中男112例,女25例;年龄26~73岁,中位年龄45岁。所有患者均签署知情同意书,符合医学伦理学规定。采用免疫组化法检测肝癌组织c-Jun蛋白表达。根据免疫组化法染色评分将患者分为高表达组(75例)和低表达组(62例)。分析两组患者临床病理学参数及c-Jun蛋白表达与生存预后的关系。两组患者临床病理学参数比较采用χ2检验,生存分析采用Kaplan-Meier法和Log-rank检验。结果肝癌c-Jun蛋白表达与患者HBs Ag、AFP、肿瘤直径、肿瘤包膜、肿瘤血管侵犯有关(χ2=5.27,32.68,4.86,1.04,4.62;P〈0.05)。高表达组患者3、5年累积生存率分别为64.14%、41.20%,低表达组相应为72.04%、61.21%,高表达组患者的总体生存率明显低于低表达组(χ2=5.19,P〈0.05)。结论 c-Jun蛋白可能在肝癌的发生、发展中起到重要作用,其高表达预示患者预后不良。 Objective To investigate the expression of c-Jun in hepatocellular carcinoma (HCC) and its correlation with prognosis. Methods Clinical data of 137 patients with HCC undergoing hepatectomy in the Third Affiliated Hospital of Sun Yat-sen University between Janunary 2010 and December 2013 were retrospectively studied. Among the 137 patients, 112 were males and 25 were females with the age ranging from 26 to 73 years old and the median of 45 years old. The informed consents of all patients were obtained and the local ethical committee approval had been received. The expression of c-Jun in HCC tissues was detected by immunohistochemistry. The patients were divided into the high-expression group (n=75) and low-expression group (n=62) according to the scores of immunohistochemical staining. The clinicopathological parameters and the correlation between c-Jun expression and prognosis of the two groups were analyzed. Comparison on clinicopathological parameters was conducted using Chi-square test and survival analysis was conducted using Kaplan-Meier and Log-rank test. Results The expression of c-Jun in HCC was correlated with HBsAg, alpha-fetoprotein (AFP), tumor size, tumor capsule and tumor vascular invasion (x^2=5.27, 32.68, 4.86, 1.04, 4.62; P〈0.05). The 3-, 5-year cumulative survival rate of the high-expression group was respectively 64.14% and 41.20% and those of the low-expression group was respectively 72.04% and 61.21%. The overall survival of the high-expression group was significantly lower than that of the low-expression group (x^2=5.19, P〈0.05). Conclusion c-Jun may play an important role in the occurrence and development of HCC and high expression of c-Jun indicates poor prognosis.
出处 《中华肝脏外科手术学电子杂志》 CAS 2015年第4期250-253,共4页 Chinese Journal of Hepatic Surgery(Electronic Edition)
基金 广东省科技计划项目(2011B61300011)
关键词 肝细胞 C-JUN 预后 Carcinoma, hepatocellular c-Jun Prognosis
  • 相关文献

参考文献19

  • 1Kang TW, Lim HK, Lee MW, et al. Perivascular versus nonperivascular small HCC treated with percutaneous RF ablation: retrospective comparison of long-term therapeutic outcomes[J]. Radiology, 2014, 270(3): 888-899. 被引量:1
  • 2范上达,邱宗祥,潘冬平.肝癌的综合治疗[J].中华消化外科杂志,2011,10(4):241-246. 被引量:37
  • 3Daniele A, Divella R, Quaranta M, et al. Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization[J]. Clin Biochem, 2014, 47(3): 184-190. 被引量:1
  • 4Finkelmeier F, Bettinger D, Koberle V, et al. Single measurement of hemoglobin predicts outcome of HCC patients[J]. Med Oncol, 2014, 31(1): 806. 被引量:1
  • 5郭宇,陈规划.肝细胞肝癌合并肝静脉、下腔静脉及右心房癌栓的诊断与治疗[J].中华肝脏外科手术学电子杂志,2013,2(1):46-48. 被引量:16
  • 6安玉玲,张婷婷,蔡常洁.西罗莫司用于治疗肝癌肝移植术后肿瘤复发患者的疗效分析[J].器官移植,2011,2(2):73-76. 被引量:15
  • 7Kim S, Lee J, Lee SK, et al. Protein kinase C- a downregulates estrogen receptor- a by suppressing c-Jun phosphorylation in estrogen receptor-positive breast cancer cells[J]. Oncol Rep, 2014, 31(3): 1423-1428. 被引量:1
  • 8Yang Z, Zhang Y, Wang L. A feedback inhibition between miRNA- 127 and TGPbeta/c-Jun cascade in HCC cell migration via MMP13[J]. PLoS One, 2013, 8(6):e65256. 被引量:1
  • 9Rana A, Rana B, Mishra R, et al. Mixed lineage Kinase-c-Jun N-Terminal kinase axis: a potential therapeutic target in cancer[J]. Genes Cancer, 2013, 4(9/10): 334-341. 被引量:1
  • 10Tinzl M, Chen B, Chen SY, et al. Interaction between c-jun and androgen receptor determines the outcome of taxane therapy in castration resistant prostate cancer[J]. PLoS One, 2013, 8( 11): e79573. 被引量:1

二级参考文献53

  • 1郑克立,王长希,陈立中,唐孝达,范昱,闵志廉,齐隽,黎磊石,刘志红,季曙明.雷帕霉素联合环孢素和皮质类固醇预防肾移植急性排斥反应的临床研究[J].中华器官移植杂志,2004,25(4):240-242. 被引量:10
  • 2Jian Zhou Jia Fan Zheng Wang Zhi-Quan Wu Shuang-Jian Qiu Xiao-Wu Huang Yao Yu Jian Sun Yong-Sheng Xiao Yi-Feng He Yu-Qi Wang Zhao-You Tang.Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma:Report of an initial experience[J].World Journal of Gastroenterology,2006,12(19):3114-3118. 被引量:20
  • 3汤钊猷.开展肝癌转移复发研究的意义与途径[J].中华普通外科杂志,2006,21(11):761-761. 被引量:34
  • 4Faivre S,Rarmond E,Boucher E,et al.Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma:an open-label,muhiceatre,phase Ⅱ study.Lancet Oncol,2009,10(8):794-800. 被引量:1
  • 5Uematsu S,Higashi T,Nouso K,et al.Altered expression of vascular endothelial growth factor,fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma.J Gastroenterol Hepato1,2005,20(4):583-588. 被引量:1
  • 6Park JW,Finn RS,Kim JS,et al.Phase Ⅱ,open-label study of brivanib as first-line therapy in patients with advanced hepatocellulas carcinoma.Clin Cancer Res,2011,17(7):1973-1983. 被引量:1
  • 7Toh H,CP,Carr BI,Knox JJ,et al.A phase Ⅱ study of ABT869 in advanced hepatocellular carcinoma(HCC):Interim analysis.ASCO 2009,May 29 to June 2,2009,Orlando[C].Chicago:ASCO,2009. 被引量:1
  • 8Abou-Alfa GK,Johnson P,Knox JJ,et al.Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma:a randomized trial.JAMA,2010,304(19):2154-2160. 被引量:1
  • 9Yau T,CP,Cheung FY,Lee AS,et al.Phase Ⅱ trial of sorafenib with capecitabine and oxaliplatin(SECOX)in patients with locally advanced or metastatic hepatocellular carcinoma.Joint ECCO 15-34th ESMO Multidisciplinary Congress,Septmber 19-23,2009[C].Berlin:European Journal of Cancer Supplements,2009. 被引量:1
  • 10Thomas MB,Morris JS,Chadha R,et al.Phase Ⅱ trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.J Clin Oncol,2009,27(6):843-850. 被引量:1

共引文献63

同被引文献127

引证文献7

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部